|
|||||
|
|
Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness |
|
| Authors: | Michael Mahler Luis E. Andrade Carlos A. Casiano Kishore Malyavantham Marvin J. Fritzler |
| Affiliation: | 1. Research &2. Development, Inova Diagnostics, San Diego, CA, USAmmahler@inovadx.com;4. Rheumatology Division, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de S?o Paulo, S?o Paulo, Brazil;5. Immunology Division, Fleury Laboratories, S?o Paulo, Brazil;6. Center for Health Disparities and Molecular Medicine, Department of Basic Sciences, Department of Medicine, Division of Rheumatology, Loma Linda University School of Medicine, Loma Linda, CA, USA;7. Development, Inova Diagnostics, San Diego, CA, USA;8. Cumming School of Medicine, University of Calgary, Calgary, Canada |
| Abstract: | Introduction: Anti-DFS70 antibodies and their clinical associations remain an immunological paradox. Unlike other antinuclear antibodies (ANA), there is a growing body of evidence that anti-DFS70 antibodies, when present in high titers and in isolation (without accompanying other antibodies), are useful to aid in the exclusion of ANA associated rheumatic diseases. Areas covered: This review aims to analyze and interpret the current published knowledge and recent findings to provide guidance in the use of anti-DFS70 antibodies to analyze associations of this unique autoantibody. Expert commentary: Although the association of anti-DFS70 antibodies is still unknown, their use as a biomarker that can aid in the exclusion of ANA related diseases is well-established. |
| Keywords: | Autoantibodies antinuclear antibodies ANA anti-DFS70 dense fine speckled ANA associated rheumatic disease indirect immunofluorescence |